Trever G. Bivona

21.6k total citations · 2 hit papers
128 papers, 7.5k citations indexed

About

Trever G. Bivona is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Trever G. Bivona has authored 128 papers receiving a total of 7.5k indexed citations (citations by other indexed papers that have themselves been cited), including 75 papers in Molecular Biology, 57 papers in Pulmonary and Respiratory Medicine and 54 papers in Oncology. Recurrent topics in Trever G. Bivona's work include Lung Cancer Treatments and Mutations (55 papers), Cancer Genomics and Diagnostics (36 papers) and Cancer Mechanisms and Therapy (15 papers). Trever G. Bivona is often cited by papers focused on Lung Cancer Treatments and Mutations (55 papers), Cancer Genomics and Diagnostics (36 papers) and Cancer Mechanisms and Therapy (15 papers). Trever G. Bivona collaborates with scholars based in United States, Spain and China. Trever G. Bivona's co-authors include Mark R. Philips, Julia Rotow, Rafael Rosell, Vi K. Chiu, Adrienne D. Cox, Nilanjana Chatterjee, Niki Karachaliou, Heidi H. Wiener, Ignacío Pérez de Castro and Amit J. Sabnis and has published in prestigious journals such as Nature, Science and Cell.

In The Last Decade

Trever G. Bivona

123 papers receiving 7.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Understanding and targeting resistance mechanisms in NSCLC

2017 684 citations Julia Rotow, Trever G. Bivona Nature reviews. Cancer profile →
Ras signalling on the endoplasmic reticulum and the Golgi

2002 516 citations Trever G. Bivona, Mark R. Philips et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Trever G. Bivona United States	43	4.9k	2.5k	1.9k	1.6k	1.0k	128	7.5k
Jianjun Yu China	26	6.4k 1.3×	1.9k 0.8×	2.4k 1.2×	2.8k 1.7×	603 0.6×	64	8.9k
Gaorav P. Gupta United States	28	5.5k 1.1×	4.4k 1.8×	1.1k 0.6×	2.9k 1.7×	817 0.8×	76	9.5k
Lalita A. Shevde United States	41	4.5k 0.9×	2.5k 1.0×	1.0k 0.5×	1.6k 1.0×	515 0.5×	105	6.9k
Toyomasa Katagiri Japan	56	6.1k 1.2×	2.3k 0.9×	1.3k 0.6×	1.6k 1.0×	876 0.9×	166	9.1k
Hui‐Wen Lo United States	48	4.5k 0.9×	3.3k 1.3×	1.5k 0.8×	1.5k 0.9×	421 0.4×	113	7.7k
Weiping Shu United States	16	4.4k 0.9×	3.8k 1.5×	1.2k 0.6×	2.2k 1.3×	612 0.6×	25	7.6k
Yongkun Wei United States	35	4.9k 1.0×	3.3k 1.3×	1.6k 0.8×	2.2k 1.3×	517 0.5×	56	7.6k
Igor Vivanco United States	20	5.0k 1.0×	2.0k 0.8×	1.3k 0.7×	1.3k 0.8×	422 0.4×	28	7.0k
Gema Moreno‐Bueno Spain	55	6.2k 1.3×	4.1k 1.6×	1.1k 0.6×	2.7k 1.6×	891 0.9×	142	10.0k
Atanasio Pandiella Spain	57	6.6k 1.3×	4.9k 1.9×	1.2k 0.6×	1.5k 0.9×	771 0.8×	284	11.6k

Countries citing papers authored by Trever G. Bivona

Since Specialization

Citations

This map shows the geographic impact of Trever G. Bivona's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Trever G. Bivona with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Trever G. Bivona more than expected).

Fields of papers citing papers by Trever G. Bivona

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Trever G. Bivona. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Trever G. Bivona. The network helps show where Trever G. Bivona may publish in the future.

Co-authorship network of co-authors of Trever G. Bivona

This figure shows the co-authorship network connecting the top 25 collaborators of Trever G. Bivona. A scholar is included among the top collaborators of Trever G. Bivona based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Trever G. Bivona. Trever G. Bivona is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lin, Zhi, Wayne Ngo, Yu‐Ting Chou, et al.. (2025). Temporal photoproximity labeling of ligand-activated EGFR neighborhoods using MultiMap. Nature Chemical Biology. 22(2). 192–204.

Riess, Jonathan W., et al.. (2024). Current Trial Report: A Multicenter Phase I/Ib study of Capmatinib Plus Trametinib in Patients With Metastatic Nonsmall Cell Lung Center Harboring MET Exon 14 Skipping Mutations and Other MET-Alterations. Clinical Lung Cancer. 25(8). 732–737. 1 indexed citations

Bivona, Trever G.. (2024). Phase-Separated Biomolecular Condensation in Cancer: New Horizons and Next Frontiers. Cancer Discovery. 14(4). 630–634.

Sinha, Sanju, Rahulsimham Vegesna, Sumit Mukherjee, et al.. (2024). PERCEPTION predicts patient response and resistance to treatment using single-cell transcriptomics of their tumors. Nature Cancer. 5(6). 938–952. 48 indexed citations

Roth, L. E., Juan Guan, Anh‐Tuan Le, et al.. (2024). Oncogenic EML4-ALK assemblies suppress growth factor perception and modulate drug tolerance. Nature Communications. 15(1). 9473–9473. 3 indexed citations

Wu, Wei, et al.. (2023). Long Non-Coding RNAs as Emerging Targets in Lung Cancer. Cancers. 15(12). 3135–3135. 14 indexed citations

Pan, Yue, Max A. Horlbeck, Jonathan S. Weissman, et al.. (2022). GATOR2-dependent mTORC1 activity is a therapeutic vulnerability in FOXO1 fusion–positive rhabdomyosarcoma. JCI Insight. 7(23). 5 indexed citations

Quinn, Jeffrey J., Matthew G. Jones, Ross A. Okimoto, et al.. (2021). Single-cell lineages reveal the rates, routes, and drivers of metastasis in cancer xenografts. Science. 371(6532). 183 indexed citations

Blakely, Collin M., et al.. (2021). Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids. Journal of Visualized Experiments. 3 indexed citations

10.

Sabnis, Amit J. & Trever G. Bivona. (2019). Principles of Resistance to Targeted Cancer Therapy: Lessons from Basic and Translational Cancer Biology. Trends in Molecular Medicine. 25(3). 185–197. 130 indexed citations

11.

Bugaj, Lukasz J., Amit J. Sabnis, Amir Mitchell, et al.. (2018). Cancer mutations and targeted drugs can disrupt dynamic signal encoding by the Ras-Erk pathway. Science. 361(6405). 107 indexed citations

12.

Neel, Dana S., Victor Olivas, Manasi K. Mayekar, et al.. (2018). Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins. Cancer Research. 79(3). 546–556. 63 indexed citations

13.

Rotow, Julia & Trever G. Bivona. (2017). Understanding and targeting resistance mechanisms in NSCLC. Nature reviews. Cancer. 17(11). 637–658. 684 indexed citations breakdown →

14.

Pavlick, Dean C., Jon Chung, Julia A. Elvin, et al.. (2017). Genomic profiling of 114,200 advanced cancers identifies recurrent kinase domain duplications (KDD) and oncogenic rearrangements (RE) across diverse tumor types. Annals of Oncology. 28. v595–v595. 4 indexed citations

15.

Zill, Oliver A., Claire Greene, Dragan Sebisanovic, et al.. (2015). Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas. Cancer Discovery. 5(10). 1040–1048. 202 indexed citations

16.

Lin, Luping, Saurabh Asthana, Elton Chan, et al.. (2014). Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer. Proceedings of the National Academy of Sciences. 111(7). E748–57. 73 indexed citations

17.

Costa, Carlota, Miguel Angel Molina, Ana Drozdowskyj, et al.. (2014). The Impact of EGFR T790M Mutations and BIM mRNA Expression on Outcome in Patients with EGFR -Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial. Clinical Cancer Research. 20(7). 2001–2010. 180 indexed citations

18.

Blakely, Collin M. & Trever G. Bivona. (2012). Resiliency of Lung Cancers to EGFR Inhibitor Treatment Unveiled, Offering Opportunities to Divide and Conquer EGFR Inhibitor Resistance. Cancer Discovery. 2(10). 872–875. 31 indexed citations

19.

Bivona, Trever G., Steven Quatela, & Mark R. Philips. (2006). Analysis of Ras Activation in Living Cells with GFP‐RBD. Methods in enzymology on CD-ROM/Methods in enzymology. 407. 128–143. 27 indexed citations

20.

Castro, Ignacío Pérez de, Trever G. Bivona, Mark R. Philips, & Àngel Pellicer. (2004). Ras Activation in Jurkat T cells following Low-Grade Stimulation of the T-Cell Receptor Is Specific to N-Ras and Occurs Only on the Golgi Apparatus. Molecular and Cellular Biology. 24(8). 3485–3496. 132 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact